This data release includes lipidomics, proteomics, and behavioral data from human cohorts and mouse models. It provides updates to the AGMP_MIND, ADNI_CSF, TyrobpKO_AppPs1, and ROSMAP studies.

Proper acknowledgment of data sources is not only mandatory for users of the AD Knowledge Portal, it also enhances the visibility of your work and elevates recognition of datasets used. All data use must be acknowledged with the following: the AD Knowledge Portal Acknowledgement Statement; and an Acknowledgement Statement specific to the study/dataset used, from the relevant Study page; and a Data Availability statement that includes a direct link to access relevant resources, known as a dataset DOI. For more information and pre-written acknowledgement statements, see Data Use & Acknowledgement.

Human

  • The Mediterranean–DASH Intervention for Neurodegenerative Delay (AGMP_MIND) study
    This study investigates the role of the MIND diet on the microbiome metabolome and its impact on cognition in a population identified as at risk of Alzheimer’s disease.

    • This release profiles 745 Rush longitudinal serum samples across four time points using the Baker lipidomics platform.
  • The ROSMAP Study
    The ROSMAP Study provides genomics, transcriptomic, epigenetic, proteomic, and metabolomic data on individuals as part of the Religious Orders Study (ROS) and the Memory and Aging Project (MAP) enrolled by the Rush Alzheimer’s Disease Center.

    • We conducted a systematic evaluation of blood biomarkers quantified in 2 NULISA™ platforms in relation to autopsy-confirmed neuropathologies. Data came from approximately 450 community-dwelling older adults enrolled in 2 cohort studies of aging and dementia. A total of 370 serum biomarkers were quantified using NULISA™ CNS Disease Panel 120 and Inflammation Panel 250 (Alamar Biosciences). Multiple serum biomarkers from the current NULISA panels are associated with cognition and clinical diagnosis of cognitive impairment and dementia in old age.
  • The ADNI_CSF Study
    CSF biomarker studies have greatly enhanced our understanding of Alzheimer’s disease (AD) pathogenesis and improved early detection and diagnostic accuracy. This TMT-based mass spectrometry proteomics study examined 1,104 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), spanning cognitively normal controls, individuals with mild cognitive impairment (MCI), and patients with AD.

    • This release profiles 1170 samples

Models

  • The TyrobpKO_AppPs1 Study
    This study provides RNA-sequencing data from the prefrontal cortex of 8-month-old mice with varying combinations of Tyrobp knockout and APP/PS1 genotypes.

    • This data release includes behavior data (learning latency and percentage distance travel) from Tyrobp knockout mice in AppPS1 background.